LGR6 modulates intervertebral disc degeneration through regulation of macrophage efferocytosis
Intervertebral disc degeneration (IVDD) is a leading cause of chronic low back pain, characterized by extracellular matrix (ECM) degradation, excessive inflammation activation, and increased cell apoptosis. LGR6, a receptor known for its role in tissue regeneration, has recently been implicated in m...
Saved in:
Published in | Journal of translational medicine Vol. 23; no. 1; pp. 475 - 25 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BMC
25.04.2025
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Intervertebral disc degeneration (IVDD) is a leading cause of chronic low back pain, characterized by extracellular matrix (ECM) degradation, excessive inflammation activation, and increased cell apoptosis. LGR6, a receptor known for its role in tissue regeneration, has recently been implicated in modulating macrophage efferocytosis, a process critical for clearing apoptotic cells and maintaining tissue homeostasis. This study aimed to investigate the role of LGR6 in regulating IVDD progression and to focus on its impact on macrophage efferocytosis, ECM regulation, and apoptosis in nucleus pulposus cells (NPCs).
A comprehensive bioinformatic analysis was performed using datasets GSE56081 and GSE70362 to identify differentially expressed genes (DEGs) and gene modules associated with IVDD. Principal component analysis (PCA), volcano plots, and hierarchical clustering were utilized to assess gene expression patterns. Weighted Gene Co-Expression Network Analysis (WGCNA) was employed to identify gene modules correlated with IVDD, and integrative analysis pinpointed key genes and pathways. In vitro, LGR6 expression in macrophages was manipulated through shRNA interference and overexpression assay. The effects of LGR6 on macrophage efferocytosis, ECM synthesis, and apoptosis were assessed. An in vivo IVDD model was established in mice via disc puncture to evaluate the impact of LGR6 modulation on disc degeneration.
Bioinformatic analysis revealed distinct gene expression profiles between control and IVDD samples, with key gene modules identified by WGCNA showing strong correlations with IVDD. Integrative analysis highlighted critical pathways, including ECM-receptor interaction and efferocytosis, that are potentially regulated by several key genes including SERPINA1, THBS4, ELMO1, LGR6, and ITGB8. Of those genes, LGR6 appeared to be the gene most closely related to IVDD severity. In addition, the mRNA level and protein level of LGR6 in macrophages co-cultured with IL-1β-treated NPCs were raised significantly, compared to the control group. In vitro, LGR6 overexpression enhanced macrophage efferocytosis. Meanwhile, under co-culturing with IL-1β-treated NPCs, LGR6 overexpression in macrophages led to increased expression of ECM components such as COL2A1 and decreased expression of matrix-degrading enzymes like MMP13, indicating a protective effect against matrix degradation. Additionally, LGR6 overexpression inhibited IL-1β-induced apoptosis in NPCs by upregulating anti-apoptotic proteins (BCL2) and downregulating pro-apoptotic markers (cleaved caspase 3 and BAX). Conversely, LGR6 knockdown impaired macrophage efferocytosis and exacerbated NPCs apoptosis. In the mouse IVDD model, promoting efferocytosis resulted in improved ECM integrity and reduced apoptosis; and suppressing efferocytosis caused opposite effect, further supporting the protective role of LGR6-related efferocytosis in IVDD.
LGR6 significantly contributes to the protective effects on IVDD by modulating macrophage efferocytosis, enhancing ECM synthesis, and reducing apoptosis in NPCs. These findings highlight that LGR6 could be a promising therapeutic target for IVDD, with its dual role in regulating immune responses and preserving tissue integrity. Future studies are necessary to evaluate the clinical potential of LGR6-based therapies in treating degenerative disc diseases. |
---|---|
AbstractList | Intervertebral disc degeneration (IVDD) is a leading cause of chronic low back pain, characterized by extracellular matrix (ECM) degradation, excessive inflammation activation, and increased cell apoptosis. LGR6, a receptor known for its role in tissue regeneration, has recently been implicated in modulating macrophage efferocytosis, a process critical for clearing apoptotic cells and maintaining tissue homeostasis. This study aimed to investigate the role of LGR6 in regulating IVDD progression and to focus on its impact on macrophage efferocytosis, ECM regulation, and apoptosis in nucleus pulposus cells (NPCs).BACKGROUND AND OBJECTIVESIntervertebral disc degeneration (IVDD) is a leading cause of chronic low back pain, characterized by extracellular matrix (ECM) degradation, excessive inflammation activation, and increased cell apoptosis. LGR6, a receptor known for its role in tissue regeneration, has recently been implicated in modulating macrophage efferocytosis, a process critical for clearing apoptotic cells and maintaining tissue homeostasis. This study aimed to investigate the role of LGR6 in regulating IVDD progression and to focus on its impact on macrophage efferocytosis, ECM regulation, and apoptosis in nucleus pulposus cells (NPCs).A comprehensive bioinformatic analysis was performed using datasets GSE56081 and GSE70362 to identify differentially expressed genes (DEGs) and gene modules associated with IVDD. Principal component analysis (PCA), volcano plots, and hierarchical clustering were utilized to assess gene expression patterns. Weighted Gene Co-Expression Network Analysis (WGCNA) was employed to identify gene modules correlated with IVDD, and integrative analysis pinpointed key genes and pathways. In vitro, LGR6 expression in macrophages was manipulated through shRNA interference and overexpression assay. The effects of LGR6 on macrophage efferocytosis, ECM synthesis, and apoptosis were assessed. An in vivo IVDD model was established in mice via disc puncture to evaluate the impact of LGR6 modulation on disc degeneration.METHODSA comprehensive bioinformatic analysis was performed using datasets GSE56081 and GSE70362 to identify differentially expressed genes (DEGs) and gene modules associated with IVDD. Principal component analysis (PCA), volcano plots, and hierarchical clustering were utilized to assess gene expression patterns. Weighted Gene Co-Expression Network Analysis (WGCNA) was employed to identify gene modules correlated with IVDD, and integrative analysis pinpointed key genes and pathways. In vitro, LGR6 expression in macrophages was manipulated through shRNA interference and overexpression assay. The effects of LGR6 on macrophage efferocytosis, ECM synthesis, and apoptosis were assessed. An in vivo IVDD model was established in mice via disc puncture to evaluate the impact of LGR6 modulation on disc degeneration.Bioinformatic analysis revealed distinct gene expression profiles between control and IVDD samples, with key gene modules identified by WGCNA showing strong correlations with IVDD. Integrative analysis highlighted critical pathways, including ECM-receptor interaction and efferocytosis, that are potentially regulated by several key genes including SERPINA1, THBS4, ELMO1, LGR6, and ITGB8. Of those genes, LGR6 appeared to be the gene most closely related to IVDD severity. In addition, the mRNA level and protein level of LGR6 in macrophages co-cultured with IL-1β-treated NPCs were raised significantly, compared to the control group. In vitro, LGR6 overexpression enhanced macrophage efferocytosis. Meanwhile, under co-culturing with IL-1β-treated NPCs, LGR6 overexpression in macrophages led to increased expression of ECM components such as COL2A1 and decreased expression of matrix-degrading enzymes like MMP13, indicating a protective effect against matrix degradation. Additionally, LGR6 overexpression inhibited IL-1β-induced apoptosis in NPCs by upregulating anti-apoptotic proteins (BCL2) and downregulating pro-apoptotic markers (cleaved caspase 3 and BAX). Conversely, LGR6 knockdown impaired macrophage efferocytosis and exacerbated NPCs apoptosis. In the mouse IVDD model, promoting efferocytosis resulted in improved ECM integrity and reduced apoptosis; and suppressing efferocytosis caused opposite effect, further supporting the protective role of LGR6-related efferocytosis in IVDD.RESULTSBioinformatic analysis revealed distinct gene expression profiles between control and IVDD samples, with key gene modules identified by WGCNA showing strong correlations with IVDD. Integrative analysis highlighted critical pathways, including ECM-receptor interaction and efferocytosis, that are potentially regulated by several key genes including SERPINA1, THBS4, ELMO1, LGR6, and ITGB8. Of those genes, LGR6 appeared to be the gene most closely related to IVDD severity. In addition, the mRNA level and protein level of LGR6 in macrophages co-cultured with IL-1β-treated NPCs were raised significantly, compared to the control group. In vitro, LGR6 overexpression enhanced macrophage efferocytosis. Meanwhile, under co-culturing with IL-1β-treated NPCs, LGR6 overexpression in macrophages led to increased expression of ECM components such as COL2A1 and decreased expression of matrix-degrading enzymes like MMP13, indicating a protective effect against matrix degradation. Additionally, LGR6 overexpression inhibited IL-1β-induced apoptosis in NPCs by upregulating anti-apoptotic proteins (BCL2) and downregulating pro-apoptotic markers (cleaved caspase 3 and BAX). Conversely, LGR6 knockdown impaired macrophage efferocytosis and exacerbated NPCs apoptosis. In the mouse IVDD model, promoting efferocytosis resulted in improved ECM integrity and reduced apoptosis; and suppressing efferocytosis caused opposite effect, further supporting the protective role of LGR6-related efferocytosis in IVDD.LGR6 significantly contributes to the protective effects on IVDD by modulating macrophage efferocytosis, enhancing ECM synthesis, and reducing apoptosis in NPCs. These findings highlight that LGR6 could be a promising therapeutic target for IVDD, with its dual role in regulating immune responses and preserving tissue integrity. Future studies are necessary to evaluate the clinical potential of LGR6-based therapies in treating degenerative disc diseases.CONCLUSIONSLGR6 significantly contributes to the protective effects on IVDD by modulating macrophage efferocytosis, enhancing ECM synthesis, and reducing apoptosis in NPCs. These findings highlight that LGR6 could be a promising therapeutic target for IVDD, with its dual role in regulating immune responses and preserving tissue integrity. Future studies are necessary to evaluate the clinical potential of LGR6-based therapies in treating degenerative disc diseases. Intervertebral disc degeneration (IVDD) is a leading cause of chronic low back pain, characterized by extracellular matrix (ECM) degradation, excessive inflammation activation, and increased cell apoptosis. LGR6, a receptor known for its role in tissue regeneration, has recently been implicated in modulating macrophage efferocytosis, a process critical for clearing apoptotic cells and maintaining tissue homeostasis. This study aimed to investigate the role of LGR6 in regulating IVDD progression and to focus on its impact on macrophage efferocytosis, ECM regulation, and apoptosis in nucleus pulposus cells (NPCs). A comprehensive bioinformatic analysis was performed using datasets GSE56081 and GSE70362 to identify differentially expressed genes (DEGs) and gene modules associated with IVDD. Principal component analysis (PCA), volcano plots, and hierarchical clustering were utilized to assess gene expression patterns. Weighted Gene Co-Expression Network Analysis (WGCNA) was employed to identify gene modules correlated with IVDD, and integrative analysis pinpointed key genes and pathways. In vitro, LGR6 expression in macrophages was manipulated through shRNA interference and overexpression assay. The effects of LGR6 on macrophage efferocytosis, ECM synthesis, and apoptosis were assessed. An in vivo IVDD model was established in mice via disc puncture to evaluate the impact of LGR6 modulation on disc degeneration. Bioinformatic analysis revealed distinct gene expression profiles between control and IVDD samples, with key gene modules identified by WGCNA showing strong correlations with IVDD. Integrative analysis highlighted critical pathways, including ECM-receptor interaction and efferocytosis, that are potentially regulated by several key genes including SERPINA1, THBS4, ELMO1, LGR6, and ITGB8. Of those genes, LGR6 appeared to be the gene most closely related to IVDD severity. In addition, the mRNA level and protein level of LGR6 in macrophages co-cultured with IL-1β-treated NPCs were raised significantly, compared to the control group. In vitro, LGR6 overexpression enhanced macrophage efferocytosis. Meanwhile, under co-culturing with IL-1β-treated NPCs, LGR6 overexpression in macrophages led to increased expression of ECM components such as COL2A1 and decreased expression of matrix-degrading enzymes like MMP13, indicating a protective effect against matrix degradation. Additionally, LGR6 overexpression inhibited IL-1β-induced apoptosis in NPCs by upregulating anti-apoptotic proteins (BCL2) and downregulating pro-apoptotic markers (cleaved caspase 3 and BAX). Conversely, LGR6 knockdown impaired macrophage efferocytosis and exacerbated NPCs apoptosis. In the mouse IVDD model, promoting efferocytosis resulted in improved ECM integrity and reduced apoptosis; and suppressing efferocytosis caused opposite effect, further supporting the protective role of LGR6-related efferocytosis in IVDD. LGR6 significantly contributes to the protective effects on IVDD by modulating macrophage efferocytosis, enhancing ECM synthesis, and reducing apoptosis in NPCs. These findings highlight that LGR6 could be a promising therapeutic target for IVDD, with its dual role in regulating immune responses and preserving tissue integrity. Future studies are necessary to evaluate the clinical potential of LGR6-based therapies in treating degenerative disc diseases. Abstract Background and objectives Intervertebral disc degeneration (IVDD) is a leading cause of chronic low back pain, characterized by extracellular matrix (ECM) degradation, excessive inflammation activation, and increased cell apoptosis. LGR6, a receptor known for its role in tissue regeneration, has recently been implicated in modulating macrophage efferocytosis, a process critical for clearing apoptotic cells and maintaining tissue homeostasis. This study aimed to investigate the role of LGR6 in regulating IVDD progression and to focus on its impact on macrophage efferocytosis, ECM regulation, and apoptosis in nucleus pulposus cells (NPCs). Methods A comprehensive bioinformatic analysis was performed using datasets GSE56081 and GSE70362 to identify differentially expressed genes (DEGs) and gene modules associated with IVDD. Principal component analysis (PCA), volcano plots, and hierarchical clustering were utilized to assess gene expression patterns. Weighted Gene Co-Expression Network Analysis (WGCNA) was employed to identify gene modules correlated with IVDD, and integrative analysis pinpointed key genes and pathways. In vitro, LGR6 expression in macrophages was manipulated through shRNA interference and overexpression assay. The effects of LGR6 on macrophage efferocytosis, ECM synthesis, and apoptosis were assessed. An in vivo IVDD model was established in mice via disc puncture to evaluate the impact of LGR6 modulation on disc degeneration. Results Bioinformatic analysis revealed distinct gene expression profiles between control and IVDD samples, with key gene modules identified by WGCNA showing strong correlations with IVDD. Integrative analysis highlighted critical pathways, including ECM-receptor interaction and efferocytosis, that are potentially regulated by several key genes including SERPINA1, THBS4, ELMO1, LGR6, and ITGB8. Of those genes, LGR6 appeared to be the gene most closely related to IVDD severity. In addition, the mRNA level and protein level of LGR6 in macrophages co-cultured with IL-1β-treated NPCs were raised significantly, compared to the control group. In vitro, LGR6 overexpression enhanced macrophage efferocytosis. Meanwhile, under co-culturing with IL-1β-treated NPCs, LGR6 overexpression in macrophages led to increased expression of ECM components such as COL2A1 and decreased expression of matrix-degrading enzymes like MMP13, indicating a protective effect against matrix degradation. Additionally, LGR6 overexpression inhibited IL-1β-induced apoptosis in NPCs by upregulating anti-apoptotic proteins (BCL2) and downregulating pro-apoptotic markers (cleaved caspase 3 and BAX). Conversely, LGR6 knockdown impaired macrophage efferocytosis and exacerbated NPCs apoptosis. In the mouse IVDD model, promoting efferocytosis resulted in improved ECM integrity and reduced apoptosis; and suppressing efferocytosis caused opposite effect, further supporting the protective role of LGR6-related efferocytosis in IVDD. Conclusions LGR6 significantly contributes to the protective effects on IVDD by modulating macrophage efferocytosis, enhancing ECM synthesis, and reducing apoptosis in NPCs. These findings highlight that LGR6 could be a promising therapeutic target for IVDD, with its dual role in regulating immune responses and preserving tissue integrity. Future studies are necessary to evaluate the clinical potential of LGR6-based therapies in treating degenerative disc diseases. |
ArticleNumber | 475 |
Author | Sun, Jingchuan Zheng, Bing Shi, Yangyang Sun, Kaiqiang Chen, Jun Li, Fudong Shi, Jiangang |
Author_xml | – sequence: 1 givenname: Fudong surname: Li fullname: Li, Fudong – sequence: 2 givenname: Yangyang surname: Shi fullname: Shi, Yangyang – sequence: 3 givenname: Jun surname: Chen fullname: Chen, Jun – sequence: 4 givenname: Jingchuan surname: Sun fullname: Sun, Jingchuan – sequence: 5 givenname: Jiangang surname: Shi fullname: Shi, Jiangang – sequence: 6 givenname: Kaiqiang surname: Sun fullname: Sun, Kaiqiang – sequence: 7 givenname: Bing surname: Zheng fullname: Zheng, Bing |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40281518$$D View this record in MEDLINE/PubMed |
BookMark | eNpNkUtr3TAQhUVJaR7tH-iieNmNU708kpYltGngQqG02wpJHvk62NatJBfy7-ubm4as5jB8cwbOuSRnS1qQkPeMXjOm4VNh3IBqKe9aCpJv6hW5YFKZttMKzl7oc3JZyj2lXHbSvCHnknLNOqYvyO_d7Q9o5tSvk6tYmnGpmP9iruizm5p-LKHpccAFs6tjWpq6z2kd9k3G4XhyXKXYzC7kdNi7ARuMEXMKDzWVsbwlr6ObCr57mlfk19cvP2--tbvvt3c3n3dtEAC1FcJ0nAYHXhsqmJOeShBGGS4DeIGqFxRUMNJFFZ1gRjmvPCgNiBJiEFfk7uTbJ3dvD3mcXX6wyY32cZHyYF2uY5jQcuepcgakiSC1jF5FioIK3WMIjOrN6-PJ65DTnxVLtfOWAk6TWzCtxW7vOwUAHdvQD0_o6mfsnx__z3cD-AnY4iklY3xGGLXHEu2pRLuVaB9LtFT8A93WjyA |
Cites_doi | 10.1111/exd.13187 10.1042/BSR20182375 10.1186/s11658-023-00517-x 10.7150/thno.78878 10.1016/j.immuni.2022.11.013 10.1016/S0140-6736(21)00733-9 10.1074/jbc.RA118.006628 10.1152/ajplung.00066.2012 10.1080/15548627.2023.2186099 10.1016/j.jad.2024.02.045 10.1182/blood-2010-02-272005 10.1038/s41388-021-02002-1 10.1038/ng.3957 10.1039/D0FO03353G 10.1016/S0140-6736(16)30970-9 10.1016/j.intimp.2022.108671 10.1136/annrheumdis-2021-221513 10.1016/j.neuron.2022.10.015 10.7150/thno.90370 10.1038/s41590-018-0249-1 10.1038/srep15662 10.1016/j.jconrel.2024.03.029 10.1186/s12943-019-1022-2 10.1016/j.bone.2023.116681 10.1302/2046-3758.121.BJR-2022-0225.R1 10.1186/s12951-023-02075-y 10.7554/eLife.83069 10.1016/j.bone.2024.117207 10.1016/j.jaci.2015.07.034 10.1016/j.stem.2021.05.007 10.7150/thno.93036 10.7150/thno.48987 10.1016/j.carbpol.2020.116757 10.3389/fmed.2021.676688 10.1074/jbc.M114.570838 10.1371/journal.pone.0127885 10.1016/j.atherosclerosis.2019.04.229 10.1016/j.omto.2019.04.002 10.1016/j.redox.2023.102763 10.1111/acel.13072 10.1039/D3FO01902K 10.1007/s10072-021-05835-6 10.1093/rheumatology/keab096 10.1038/s42255-023-00736-8 10.1002/adma.202313248 10.15252/emmm.202317815 10.1038/s41467-024-44886-z |
ContentType | Journal Article |
Copyright | 2025. The Author(s). |
Copyright_xml | – notice: 2025. The Author(s). |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 DOA |
DOI | 10.1186/s12967-025-06427-0 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1479-5876 |
EndPage | 25 |
ExternalDocumentID | oai_doaj_org_article_2ab07a9649f6484fb7f0e3038decc108 40281518 10_1186_s12967_025_06427_0 |
Genre | Journal Article |
GrantInformation_xml | – fundername: Shanghai Sailing Program grantid: 23YF1459100 – fundername: National Natural Science Foundation of China grantid: 82472493 – fundername: National Natural Science Foundation of China grantid: 82172381 – fundername: High Achievement Cultivation Plan of Changzheng Hospital grantid: 2020YCGPZ106 – fundername: National Natural Science Foundation of China grantid: 82302760 – fundername: Shanghai Municipal Hospital Development Center grantid: SHDC2020CR1024B |
GroupedDBID | --- 0R~ 29L 2WC 53G 5VS 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACUHS ADBBV ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ TR2 TUS UKHRP WOQ WOW XSB ~8M CGR CUY CVF ECM EIF NPM 7X8 PUEGO |
ID | FETCH-LOGICAL-c366t-339520ca6b89031a4b046397924c6b3e7d3067c94af7fa3197ab7b6786ee46fc3 |
IEDL.DBID | DOA |
ISSN | 1479-5876 |
IngestDate | Wed Aug 27 00:23:26 EDT 2025 Fri Jul 11 18:30:44 EDT 2025 Mon Jul 21 05:46:05 EDT 2025 Tue Aug 05 12:13:31 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Efferocytosis Intervertebral disc degeneration Nucleus pulposus LGR6 Macrophages Apoptosis |
Language | English |
License | 2025. The Author(s). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c366t-339520ca6b89031a4b046397924c6b3e7d3067c94af7fa3197ab7b6786ee46fc3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://doaj.org/article/2ab07a9649f6484fb7f0e3038decc108 |
PMID | 40281518 |
PQID | 3195766651 |
PQPubID | 23479 |
PageCount | 25 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_2ab07a9649f6484fb7f0e3038decc108 proquest_miscellaneous_3195766651 pubmed_primary_40281518 crossref_primary_10_1186_s12967_025_06427_0 |
PublicationCentury | 2000 |
PublicationDate | 2025-04-25 |
PublicationDateYYYYMMDD | 2025-04-25 |
PublicationDate_xml | – month: 04 year: 2025 text: 2025-04-25 day: 25 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Journal of translational medicine |
PublicationTitleAlternate | J Transl Med |
PublicationYear | 2025 |
Publisher | BMC |
Publisher_xml | – name: BMC |
References | Z Kamali Amir (6427_CR10) 2021; 11 K Rovati Lucrezia (6427_CR35) 2021; 60 KN Nick (6427_CR1) 2021; 398 S Yoshida (6427_CR17) 2012; 303 G Romero-Molina Carmen (6427_CR30) 2022; 110 D Laura (6427_CR36) 2023; 169 H Wang Xiaochen (6427_CR23) 2023; 56 D Wang (6427_CR46) 2023; 19 L Feng Qian (6427_CR40) 2021; 40 M Xie Chenglong (6427_CR21) 2021; 12 M Lei (6427_CR11) 2023; 28 T Nash William (6427_CR22) 2021; 8 S Zhao Xin (6427_CR5) 2023; 21 N Schilperoort Maaike (6427_CR6) 2023; 5 V Myers Kayla (6427_CR31) 2019; 18 T Elder Craig (6427_CR42) 2021; 35 Y Xiao (6427_CR18) 2024; 352 L Kourtzelis Ioannis (6427_CR24) 2019; 20 B Li (6427_CR8) 2023; 13 WM-YG Yun-Jun (6427_CR25) 2023; 15 O Liu Xiong (6427_CR27) 2024; 369 W Jiang Lichun (6427_CR38) 2017; 26 S King Justin (6427_CR39) 2024; 187 R Fernandez-Boyanapalli (6427_CR16) 2010; 116 S Xu Jiawen (6427_CR3) 2023; 12 Q Feng (6427_CR48) 2021; 40 J Fan Linfeng (6427_CR32) 2024; 14 Y Zihao (6427_CR26) 2023; 12 K Huang Sixia (6427_CR37) 2021; 28 Y Nishi Chihiro (6427_CR7) 2019; 294 F Jiang Yanhai (6427_CR4) 2019; 39 X Ruan (6427_CR49) 2019; 14 M Zhaoxin (6427_CR20) 2022; 107 F Wang (6427_CR45) 2018; 42 Z Kazezian (6427_CR12) 2015; 5 K Sun (6427_CR13) 2024; 36 6427_CR15 G Singh (6427_CR19) 2020; 247 KJ-M Quan Hui (6427_CR34) 2015; 10 N Nguyen Khanh-Quynh (6427_CR33) 2014; 289 R Ma Tianwen (6427_CR41) 2023; 14 M-N Saiko (6427_CR14) 2019; 286 U Maher Chris (6427_CR2) 2017; 389 Y Huang Phillips (6427_CR43) 2017; 49 6427_CR29 T Taheri Forough (6427_CR9) 2022; 43 L Wang Yue (6427_CR28) 2023; 64 D Kim (6427_CR44) 2020; 19 H Zhang (6427_CR47) 2022; 81 C Cohen (6427_CR50) 2024; 15 |
References_xml | – volume: 26 start-page: 105 issue: 2 year: 2017 ident: 6427_CR38 publication-title: Exp Dermatol doi: 10.1111/exd.13187 – volume: 39 start-page: BSR20182375 issue: 2 year: 2019 ident: 6427_CR4 publication-title: Biosci Rep doi: 10.1042/BSR20182375 – volume: 28 start-page: 104 year: 2023 ident: 6427_CR11 publication-title: Cell Mol Biol Lett doi: 10.1186/s11658-023-00517-x – volume: 13 start-page: 231 issue: 1 year: 2023 ident: 6427_CR8 publication-title: Theranostics doi: 10.7150/thno.78878 – volume: 56 start-page: 58 issue: 1 year: 2023 ident: 6427_CR23 publication-title: Immunity doi: 10.1016/j.immuni.2022.11.013 – volume: 398 start-page: 78 issue: 10294 year: 2021 ident: 6427_CR1 publication-title: Lancet doi: 10.1016/S0140-6736(21)00733-9 – volume: 294 start-page: 7221 issue: 18 year: 2019 ident: 6427_CR7 publication-title: J Biol Chem doi: 10.1074/jbc.RA118.006628 – volume: 303 start-page: L852 year: 2012 ident: 6427_CR17 publication-title: Am J Physiol Lung Cell Mol Physiol doi: 10.1152/ajplung.00066.2012 – volume: 19 start-page: 2485 issue: 9 year: 2023 ident: 6427_CR46 publication-title: Autophagy doi: 10.1080/15548627.2023.2186099 – volume: 352 start-page: 76 year: 2024 ident: 6427_CR18 publication-title: J Affect Disord doi: 10.1016/j.jad.2024.02.045 – volume: 116 start-page: 4512 year: 2010 ident: 6427_CR16 publication-title: Blood doi: 10.1182/blood-2010-02-272005 – volume: 40 start-page: 6103 issue: 42 year: 2021 ident: 6427_CR48 publication-title: Oncogene doi: 10.1038/s41388-021-02002-1 – volume: 49 start-page: 1624 issue: 11 year: 2017 ident: 6427_CR43 publication-title: Nat Genet doi: 10.1038/ng.3957 – volume: 12 start-page: 2703 issue: 6 year: 2021 ident: 6427_CR21 publication-title: Food Funct doi: 10.1039/D0FO03353G – volume: 389 start-page: 736 issue: 10070 year: 2017 ident: 6427_CR2 publication-title: Lancet doi: 10.1016/S0140-6736(16)30970-9 – volume: 107 start-page: 108671 year: 2022 ident: 6427_CR20 publication-title: Int Immunopharmacol doi: 10.1016/j.intimp.2022.108671 – volume: 81 start-page: 676 issue: 5 year: 2022 ident: 6427_CR47 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2021-221513 – volume: 110 start-page: 3513 issue: 21 year: 2022 ident: 6427_CR30 publication-title: Neuron doi: 10.1016/j.neuron.2022.10.015 – volume: 14 start-page: 283 issue: 1 year: 2024 ident: 6427_CR32 publication-title: Theranostics doi: 10.7150/thno.90370 – volume: 20 start-page: 40 issue: 1 year: 2019 ident: 6427_CR24 publication-title: Nat Immunol doi: 10.1038/s41590-018-0249-1 – volume: 5 start-page: 15662 year: 2015 ident: 6427_CR12 publication-title: Sci Rep doi: 10.1038/srep15662 – volume: 369 start-page: 215 year: 2024 ident: 6427_CR27 publication-title: J Control Release doi: 10.1016/j.jconrel.2024.03.029 – volume: 18 start-page: 94 issue: 1 year: 2019 ident: 6427_CR31 publication-title: Mol Cancer doi: 10.1186/s12943-019-1022-2 – volume: 169 start-page: 116681 year: 2023 ident: 6427_CR36 publication-title: Bone doi: 10.1016/j.bone.2023.116681 – volume: 12 start-page: 80 issue: 1 year: 2023 ident: 6427_CR3 publication-title: Bone Joint Res doi: 10.1302/2046-3758.121.BJR-2022-0225.R1 – volume: 21 start-page: 317 issue: 1 year: 2023 ident: 6427_CR5 publication-title: J Nanobiotechnol doi: 10.1186/s12951-023-02075-y – volume: 12 start-page: e83069 year: 2023 ident: 6427_CR26 publication-title: Elife doi: 10.7554/eLife.83069 – volume: 187 start-page: 117207 year: 2024 ident: 6427_CR39 publication-title: Bone doi: 10.1016/j.bone.2024.117207 – ident: 6427_CR15 doi: 10.1016/j.jaci.2015.07.034 – volume: 40 start-page: 6103 issue: 42 year: 2021 ident: 6427_CR40 publication-title: Oncogene doi: 10.1038/s41388-021-02002-1 – volume: 35 start-page: e21780 issue: 8 year: 2021 ident: 6427_CR42 publication-title: FASEB J – volume: 28 start-page: 1582 issue: 9 year: 2021 ident: 6427_CR37 publication-title: Cell Stem Cell doi: 10.1016/j.stem.2021.05.007 – volume: 42 start-page: 625 issue: 1 year: 2018 ident: 6427_CR45 publication-title: Int J Mol Med – ident: 6427_CR29 doi: 10.7150/thno.93036 – volume: 11 start-page: 27 issue: 1 year: 2021 ident: 6427_CR10 publication-title: Theranostics doi: 10.7150/thno.48987 – volume: 247 start-page: 116757 year: 2020 ident: 6427_CR19 publication-title: Carbohydr Polym doi: 10.1016/j.carbpol.2020.116757 – volume: 8 start-page: 676688 year: 2021 ident: 6427_CR22 publication-title: Front Med (Lausanne) doi: 10.3389/fmed.2021.676688 – volume: 289 start-page: 25737 issue: 37 year: 2014 ident: 6427_CR33 publication-title: J Biol Chem doi: 10.1074/jbc.M114.570838 – volume: 10 start-page: e0127885 issue: 5 year: 2015 ident: 6427_CR34 publication-title: PLoS ONE doi: 10.1371/journal.pone.0127885 – volume: 286 start-page: 30 year: 2019 ident: 6427_CR14 publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2019.04.229 – volume: 14 start-page: 94 year: 2019 ident: 6427_CR49 publication-title: Mol Ther Oncolytics doi: 10.1016/j.omto.2019.04.002 – volume: 64 start-page: 102763 year: 2023 ident: 6427_CR28 publication-title: Redox Biol doi: 10.1016/j.redox.2023.102763 – volume: 19 start-page: e13072 issue: 3 year: 2020 ident: 6427_CR44 publication-title: Aging Cell doi: 10.1111/acel.13072 – volume: 14 start-page: 9999 issue: 22 year: 2023 ident: 6427_CR41 publication-title: Food Funct doi: 10.1039/D3FO01902K – volume: 43 start-page: 1593 issue: 3 year: 2022 ident: 6427_CR9 publication-title: Neurol Sci doi: 10.1007/s10072-021-05835-6 – volume: 60 start-page: 4929 issue: 10 year: 2021 ident: 6427_CR35 publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/keab096 – volume: 5 start-page: 431 issue: 3 year: 2023 ident: 6427_CR6 publication-title: Nat Metab doi: 10.1038/s42255-023-00736-8 – volume: 36 start-page: e2313248 issue: 19 year: 2024 ident: 6427_CR13 publication-title: Adv Mater doi: 10.1002/adma.202313248 – volume: 15 start-page: e17815 issue: 12 year: 2023 ident: 6427_CR25 publication-title: EMBO Mol Med doi: 10.15252/emmm.202317815 – volume: 15 start-page: 743 issue: 1 year: 2024 ident: 6427_CR50 publication-title: Nat Commun doi: 10.1038/s41467-024-44886-z |
SSID | ssj0024549 |
Score | 2.4296296 |
Snippet | Intervertebral disc degeneration (IVDD) is a leading cause of chronic low back pain, characterized by extracellular matrix (ECM) degradation, excessive... Abstract Background and objectives Intervertebral disc degeneration (IVDD) is a leading cause of chronic low back pain, characterized by extracellular matrix... |
SourceID | doaj proquest pubmed crossref |
SourceType | Open Website Aggregation Database Index Database |
StartPage | 475 |
SubjectTerms | Animals Apoptosis Apoptosis - genetics Efferocytosis Extracellular Matrix - metabolism Gene Expression Profiling Gene Expression Regulation Gene Regulatory Networks Humans Intervertebral disc degeneration Intervertebral Disc Degeneration - genetics Intervertebral Disc Degeneration - metabolism Intervertebral Disc Degeneration - pathology LGR6 Macrophages Macrophages - metabolism Macrophages - pathology Male Mice Nucleus pulposus Nucleus Pulposus - metabolism Nucleus Pulposus - pathology Phagocytosis Receptors, G-Protein-Coupled - genetics Receptors, G-Protein-Coupled - metabolism |
Title | LGR6 modulates intervertebral disc degeneration through regulation of macrophage efferocytosis |
URI | https://www.ncbi.nlm.nih.gov/pubmed/40281518 https://www.proquest.com/docview/3195766651 https://doaj.org/article/2ab07a9649f6484fb7f0e3038decc108 |
Volume | 23 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1JS8QwFA4uIF7E3XEZIniTYpc0y9ERF0RFBoXBgyFJUx3QqUzrwX_vS9KKHsSLl1JKIOn38paPvLyH0EGe2pSovABFMnFEEq0iTgSLUnAtieLCMOWzfG_oxT25HOWjb62-XE5YKA8cgDtKlY6ZEpSIkhJOSs3K2ILd5QVMnoRrvuDzOjLVVdkD2tNdkeH0qAavBgbBtW51ATe8_XBDvlr_7yGmdzVny2ipjRHxcVjbCpqxk1W0cN2egq-hx6vzIcWvVeFab9kaj0Pe4rRxh8Av2F20xYV98gWlHe64bcaDp6HxvPtUlfhVufZdz2BQsMvqAE_20VT1uF5H92endycXUdsnITIZpU2UZSJPY6Oo5gJ0VBHtyoAJBtTKUJ1ZVjheYARRJSsV6BxTmmnwUtRaQkuTbaC5STWxWwgrARaQaZObuCSGWSBDoMAmyTVMQHncQ4cdbPItlMOQnkZwKgPIEkCWHmQJowcO2a-RrpS1_wAClq2A5V8C7qH9Ti4Str47z1ATW73XEv4E2BKledJDm0FgX1MBLeYQzPDt_1jCDlpM_d4hUZrvorlm-m73IBZpdB_NshHro_nB6c3tsO83ITyHg4dP7F_d1g |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=LGR6+modulates+intervertebral+disc+degeneration+through+regulation+of+macrophage+efferocytosis&rft.jtitle=Journal+of+translational+medicine&rft.au=Li%2C+Fudong&rft.au=Shi%2C+Yangyang&rft.au=Chen%2C+Jun&rft.au=Sun%2C+Jingchuan&rft.date=2025-04-25&rft.issn=1479-5876&rft.eissn=1479-5876&rft.volume=23&rft.issue=1&rft.spage=475&rft_id=info:doi/10.1186%2Fs12967-025-06427-0&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1479-5876&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1479-5876&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1479-5876&client=summon |